Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Bioventus Expects FY24 Net Sales of $520M-$535M Vs $517.82M Est, Adj EPS of EPS of $0.12-$0.20 Vs $0.33 Est

Author: Benzinga Newsdesk | March 12, 2024 07:56am

Posted In: BVS